- WORX ripped higher in premarket trading (up ~52% to ~$0.44) and continued to spike after the open. Benzinga
- Intraday, the stock briefly more than doubled (ChartMill flagged WORX among the day’s biggest “gappers”). ChartMill
- No fresh company press release or SEC filing today as of publication; the most recent company updates were in October (Nasdaq compliance extension and a 3‑year contract renewal). SCWorx, Corp.
- Next known catalyst: SCWorx’s Annual Meeting on Dec. 8, 2025, where shareholders will vote on proposals including authorizing more shares and equity plans. SEC
What happened today
- Premarket momentum: WORX appeared on multiple “movers” dashboards before the bell, up ~52% around $0.44. Benzinga
- At-the-open follow‑through: During regular trading hours, ChartMill flagged WORX as a top “gapper,” noting a >100% intraday jump at one point. Micro‑cap names like WORX can see outsized percentage moves when liquidity floods in. ChartMill
Important context: There is no new company‑issued news stamped Nov. 6, 2025 on SCWorx’s investor relations page or the SEC feed. The last press releases were Oct. 14 (Nasdaq extension) and Oct. 6 (contract renewal). SCWorx, Corp.
Is there a catalyst?
October headlines still in focus
- Nasdaq minimum bid price extension: SCWorx said Nasdaq granted a second 180‑day window—until April 6, 2026—to regain $1.00 compliance. The company added it may implement a reverse split if needed. This was disclosed via an 8‑K and IR press release in mid‑October. SCWorx, Corp.+1
- Commercial update: On Oct. 6, SCWorx announced a three‑year renewal with an existing healthcare customer, lifting the contract value ~113% versus the prior term. SCWorx, Corp.
Today’s move looks technical
Given the absence of a new filing or press release today, the spike appears trading‑driven (momentum/technicals) rather than news‑driven. Micro‑floats can move quickly when liquidity concentrates.
Float & short interest (context):
- Yahoo Finance recently listed ~7.7M shares in the free float (provider estimates vary as outstanding shares change with conversions). Yahoo Finance
- MarketBeat’s late‑October read showed ~14.9% of float sold short, which can amplify swings. MarketBeat
What to watch next
1) Annual Meeting — Dec. 8, 2025
SCWorx’s definitive proxy (filed for the Dec. 8 meeting) asks shareholders to vote on several items, including:
- Increasing authorized shares from 45,000,000 to 155,000,000 (of which 150,000,000 would be common stock).
- Authorizing share issuances under Nasdaq Rule 5635(d) tied to previously issued and prospective warrants/convertible notes.
- Approving the 2025 Equity Incentive Plan.
- Ratifying the auditor (Astra Audit & Advisory, LLC).
Record date was Oct. 10, 2025; the proxy shows 12,105,650 common shares outstanding on that date and 39,810 preferred shares convertible into ~1.14M common shares. SEC
2) Nasdaq compliance clock — through April 6, 2026
SCWorx must achieve a $1.00+ closing bid for at least 10 consecutive trading days by the deadline to remain compliant; otherwise, it has indicated it may effect a reverse split within the range previously approved by shareholders. SCWorx, Corp.+1
Company snapshot (latest filed figures)
From SCWorx’s most recent 10‑Q for the quarter ended June 30, 2025 (filed Aug. 14):
- Six‑month revenue:$1.40M (vs. $1.55M YoY).
- Six‑month net loss:$2.38M (vs. $0.52M YoY), with management noting going‑concern uncertainties. SEC
Background note: In 2024, a former SCWorx CEO was convicted in a separate securities‑fraud case related to pandemic‑era test‑kit claims—context that still shades investor sentiment in micro‑cap healthcare data names. Reuters
Bottom line
- Today’s (Nov. 6) spike in WORX appears trader‑driven in the absence of fresh company news, amplified by small float/short dynamics and a flood of volume. MarketBeat+3Benzinga+3ChartMill+3
- Fundamental/structural watch‑items remain the Dec. 8 annual meeting proposals (share authorization & equity plan) and Nasdaq bid‑price compliance by April 6, 2026. SEC+1
This article is for informational purposes only and not investment advice. Always do your own research and consider consulting a licensed financial advisor.
